Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Pharma
Argenx cans Vyvgart trials in thyroid eye disease over futility
Argenx is discontinuing its late-stage UplighTED studies of subcutaneous efgartigimod in adults with moderate to severe thyroid eye disease.
Fraiser Kansteiner
Dec 15, 2025 10:00am
Otsuka wins FDA nod in ever-more-crowded kidney disease space
Nov 26, 2025 11:10am
Lilly-XtalPi, Celltrion, Illumina in China—Fierce Pharma Asia
Nov 7, 2025 9:41am
Argenx lays out details on Vyvgart's seronegative gMG win
Oct 29, 2025 2:34pm
Roche pads case for Gazyva in immune-mediated kidney conditions
Oct 28, 2025 9:55am
Fierce Biotech
Diabetes drug soothes brain inflammation in female mice with MS
Oct 15, 2025 6:16pm
